- Home
- Publications
- Publication Search
- Publication Details
Title
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 388, Issue 5, Pages 406-417
Publisher
Massachusetts Medical Society
Online
2022-12-29
DOI
10.1056/nejmoa2208822
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
- (2022) Raquel Viana et al. NATURE
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
- (2022) Yunlong Cao et al. NATURE
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
- (2022) Jennifer Hammond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
- (2022) Hong-jie Qian et al. ACTA PHARMACOLOGICA SINICA
- Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
- (2022) Cristina Menni et al. LANCET
- Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21
- (2022) Haidong Wang et al. LANCET
- Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic
- (2022) Xinxin Zhang et al. LANCET
- Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis
- (2022) Ryan M Barber et al. LANCET
- Modeling transmission of SARS-CoV-2 Omicron in China
- (2022) Jun Cai et al. NATURE MEDICINE
- The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants
- (2022) Liu Cao et al. Science Translational Medicine
- Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
- (2022) Alexandra Schäfer et al. Science Translational Medicine
- An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
- (2022) Yinzhong Shen et al. Emerging Microbes & Infections
- Fighting Omicron epidemic in China: Real-world big data from Fangcang shelter hospital during the outbreak in Shanghai 2022
- (2022) Lingying Ye et al. JOURNAL OF INFECTION
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2
- (2021) Daibao Wei et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
- (2021) Yuanchao Xie et al. CELL RESEARCH
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- (2021) Robert L. Gottlieb et al. NEW ENGLAND JOURNAL OF MEDICINE
- REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- (2021) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiviral pills could change pandemic’s course
- (2021) Jennifer Couzin-Frankel SCIENCE
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
- (2021) Dafydd R. Owen et al. SCIENCE
- A living WHO guideline on drugs for covid-19
- (2020) François Lamontagne et al. BMJ-British Medical Journal
- Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction
- (2013) Reneé de Waal et al. PLoS One
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now